Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals

International Journal of Cardiology

Volumn 104, Issue 3, 2005, Pages 251-256

  Hirsch, Mark ^a   O'Donnell, John ^a   Olsson, Anders ^b  

^a ASTRAZENECA   (United Kingdom)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Atorvastatin; Cost effectiveness; LDL C goals; Rosuvastatin

Indexed keywords

ATORVASTATIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH CARE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PATIENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; TITRIMETRY;

ADOLESCENT; ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; EUROPE; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; NORTH AMERICA; PYRIMIDINES; PYRROLES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SULFONAMIDES; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 25444521250     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2004.09.015     Document Type: Article

References (40)

1. D. Jacobs, H. Blackburn, M. Higgins, D. Reed, H. Iso, and G. McMillan Report of the conference on low blood cholesterol: mortality associations Circulation 86 1992 1046 1060
2. J. Stamler, O. Vaccaro, J.D. Neaton, and D. Wentworth Diabetes, other risk factors and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial Diabetes Care 16 1993 434 444
3. M.R. Law, N.J. Wald, and S.G. Thompson By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 308 1994 367 372
4. Coronary Drug Project Research Group Clofibrate and niacin in coronary heart disease JAMA 231 1975 360 381
5. The Lipid Research Clinics Program The lipid research clinics coronary primary prevention trials results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering JAMA 251 1984 365 374
6. P.L. Canner, K.G. Berge, N.K. Wenger, J. Stamler, L. Friedman, and R.J. Prineas Fifteen year mortality in coronary drug project patients: long-term benefit with niacin J Am Coll Cardiol 8 1986 1245 1255
7. M.H. Frick, O. Elo, K. Haapa, O.P. Heinonen, P. Heinsalmi, and P. Helo Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease N Engl J Med 317 1987 1237 1245
8. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
9. J. Shepherd, S.M. Cobbe, I. Ford, C.G. Isles, A.R. Lorimer, and P.W. MacFarlane Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N Engl J Med 333 1995 1301 1307
10. J. Shepherd Resource management in prevention of coronary heart disease: optimising prescription of lipid-lowering drugs Lancet 359 2002 2271 2273
11. F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, and T.G. Cole The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators N Engl J Med 335 1996 1001 1009
12. J.R. Downs, M. Clearfield, S. Weis, E. Whitney, D.R. Shapiro, and P.A. Beere Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. Air force/Texas coronary atherosclerosis prevention study JAMA 279 1998 1615 1622
13. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349 1357
14. G. De Backer, E. Ambrosioni, K. Borch-Johnsen, C. Brotons, R. Cifkova, and J. Dallongeville European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice Eur Heart J 24 2003 1601 1610
15. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III; final report) Circulation 106 2002 3143 3421
16. Heart Protection Study Collaborative Group MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
17. J.L. Liu, N. Maniadakis, A. Gray, and M. Rayner The economic burden of coronary heart disease in the UK Heart 88 2002 597 603
18. S. Petersen, V. Peto, and M. Rayner Coronary heart disease statistics 2003 British Heart Foundation London
19. M. Pignone, C. Phillips, and C. Mulrow Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials BMJ 321 2001 983 986
20. IMS Health, IMS MIDAS [MAT Q3/03].
21. M. Davidson, P. Ma, E.A. Stein, A.M. Gotto Jr., A. Raza, and R. Chitra Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia Am J Cardiol 89 2002 268 275
22. A.G. Olsson, H. Istad, O. Luurila, L. Ose, S. Stender, and J. Tuomilehto Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia Am Heart J 144 2002 1044 1051
23. P.H. Jones, M.H. Davidson, E.A. Stein, H.E. Bays, J.M. McKenney, and E. Miller Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial) Am J Cardiol 92 2003 152 160
24. D.W. Schneck, R.H. Knopp, C.M. Ballantyne, R. McPherson, R.R. Chitra, and S.G. Simonson Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease Am J Cardiol 91 2003 33 41
25. H. Schuster, P.J. Barter, S. Stender, R.C. Cheung, J. Bonnet, and J.M. Morrell Effects of switching statins on achievement of lipid goals: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study Am Heart J 147 2004 705 712
26. British Medical Association and Royal Pharmaceutical Society of Great Britain British National Formulary vol. 46 2003 (September) British Medical Association and Royal Pharmaceutical Society of Great Britain London
27. M. Davidson, J. McKenney, E. Stein, H. Schrott, R. Bakker-Arkema, and R. Fayyad Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I Am J Cardiol 79 1997 1475 1481
28. J.W. Blasetto, E.A. Stein, W.V. Brown, R. Chitra, and A. Raza Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups Am J Cardiol 91 Suppl. 5A 2003 3C 10C
29. J. Shepherd, D.B. Hunninghake, P. Barter, J.M. McKenney, and H.G. Hutchinson Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals Am J Cardiol 91 Suppl. 5A 2003 11C 19C
30. P. Durrington The human and economic costs of undertreatment with statins Int J Clin Pract 56 2002 357 368
31. EUROASPIRE II Study Group Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II Euro heart survey programme Eur Heart J 22 2001 554 572
32. S. DeWilde, I.M. Carey, S.A. Bremner, N. Richards, S.R. Hilton, and D.G. Cook Evolution of statin prescribing 1994-2001: a case of agism but not of sexism? Heart 89 2003 417 421
33. D.M. Huse, M.W. Russell, J.D. Miller, D.F. Kraemer, R.B. D'Agostino, and R.C. Ellison Cost-effectiveness of statins Am J Cardiol 82 1998 1357 1363
34. M.J. Koren, D.G. Smith, D.B. Hunninghake, M.H. Davidson, J.M. McKenney, and S.R. Weiss The cost of reaching national cholesterol education program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin Pharmacoeconomics 14 1998 59 70
35. W.J. Elliott, and D.R. Weir Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction Am J Health Syst Pharm 56 1999 1726 1732
36. D.G. Smith, S.J. Leslie, T.D. Suczs, S. McBride, L.M. Campbell, and C. Calvo Cost of treating to a modified European Atherosclerosis Society LDL-C target. Comparison of atorvastatin with fluvastatin, pravastatin and simvastatin Clin Drug Investig 17 1999 185 193
37. D.E. Hilleman, S.M. Heineman, and P.A. Foral Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: an analysis based on the CURVES study Pharmacotherapy 20 2000 819 822
38. G.D. Maclaine, and H. Patel A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels Int J Clin Pract 55 2001 243 249
39. D.O. Fedder, C.E. Koro, and G.J. L'Italien New national cholesterol education program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population Circulation 105 2002 152 156
40. A. Dart, G. Jerums, G. Nicholson, M. d'Emden, I. Hamilton-Craig, and G. Tallis A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia Am J Cardiol 80 1997 39 44